Скачать
NNZ-2591 as a Potential Treatment for Prader-Willi Syndrome
Автор: Foundation For Prader-Willi Research
Загружено: 2024-03-19
Просмотров: 461
Описание:
Neuren Pharmaceuticals is conducting a Phase 2 study of NNZ-2591 to evaluate its safety, tolerability, and efficacy in treating children, ages 4 to 12, with PWS. Watch this presentation to learn more about the trial design, participation details, and eligibility.
Доступные форматы для скачивания:
Скачать видео mp4
-
Информация по загрузке:
